Ovarian Cancer
New findings from K.M. Moxley and co-researchers in the area of ovarian cancer described
Published in Drug Law Weekly, January 12th, 2010
In this recently published article, scientists in the United States conducted a study "To assess the abilities of cisplatin, paclitaxel, and flexible heteroarotinoid (Flex-Het) compound (SHetA2) to sensitize ovarian cancer cells to induction of the extrinsic apoptosis pathway by death receptor ligands, tumor necrosis factor alpha (TNF alpha), and TNF-related apoptosis-inducing ligand (TRAIL). The effects of various combinations of TNF alpha, TRAIL, cisplatin, paclitaxel, and SHetA2 on viability and apoptosis in two established ovarian cancer cell lines, A2780 and SK-OV-3, and normal human primary endometrial cultures were measured with a cytotoxicity assay, flow cytometric analysis of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
Source: Drug Law Weekly (2010-01-12)
More Articles from Drug Law Weekly
- Adventrx Pharmaceuticals Inc.
ADVENTRX Pharmaceuticals Announces Financing - Clinical Trial Research
New findings reported from University of Nottingham describe advances in clinical trial research - Coalition for Pulmonary Fibrosis
Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn - CSL Behring
CSL Behring Awards Fourth Round of LEAD Grants Supporting Patient Organization Advocacy - Life Sciences
New life sciences research reported from Cornell University - Life Sciences
Scientists at University of Otago publish new data on life sciences - More from this issue of Drug Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
